Quote:Both programs only allow use of the unapproved drug AFTER ALL APPROVED TREATMENTS HAVE FAILED.
Actually, it's if there are no comparable or alternative therapies. In reality what that means is several treatment failures. Where leronlimab has the edge and why so many have used it under the EIND protocol is its safety profile.